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Abstract 
 
Besnoitia (B.) besnoiti is a cyst-forming apicomplexan parasite responsible for bovine 
besnoitiosis, a re-emerging disease in Europe with both cutaneous and systemic 
manifestations. The significant morbidity, lack of treatment and production losses 
associated make specific, sensitive, rapid and economic diagnosis imperative.  
 
Thirteen monoclonal antibodies (mAbs) were previously produced against a membrane-
enriched extracts of B. besnoiti tachyzoites (Apure-BbELISA Ag) and now characterized 
by Immunoblot assay and Indirect enzyme linked immunosorbent assay (iELISA). Hence, 
in order to meet the needs for a diagnostic method that would be accurate and easy to 
apply in the area of animal health, a study was undertaken to develop the first mAb-based 
competitive ELISA (Bb-cELISA1) at Friedrich-Loeffler-Institut (FLI) in Germany. 
 
A total of 948 cattle sera were used to evaluate the Bb-cELISA1. The results were 
compared with previous iELISA results and revealed 99 per cent sensibility and 99.7 per 
cent specificity. 
 
Keywords: Monoclonal antibody, competitive ELISA, bovine besnoitiosis, Besnoitia 
besnoiti, mAb-cELISA1 
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Resumo 
 
O primeiro ELISA de competição para um diagnóstico sensível e específico 
de besnoitiose utilizando um anticorpo monoclonal contra Besnoitia 
besnoiti 
 
Besnoitia (B.) besnoiti é um parasita apicomplexa formador de quistos, responsável pela 
besnoitiose bovina, uma doença re-emergente na Europa com manifestações cutâneas e 
sistémicas. A morbilidade, inexistência de tratamento e perdas produtivas associadas, 
tornam imperativo um diagnóstico específico, sensível, rápido e económico. 
Treze anticorpos monoclonais (mAbs) anteriormente produzidos face a um extrato de 
membrana enriquecida de taquizoítos de B. besnoiti (Apure-BbELISA Ag) foram agora 
caracterizados através de Immunoblot e Indirect enzyme linked immunosorbent assay 
(iELISA). Consequentemente, com o objetivo de encontrar um método diagnóstico que 
seja exato e fácil de aplicar na área da saúde animal, o trabalho foi realizado para 
desenvolver o primeiro mAb-based ELISA competitivo (Bb-cELISA1) no Friedrich-
Loeffler-Institut (FLI) na Alemanha. 
Foram utilizados 948 soros de bovino para avaliar o Bb-cELISA1. Os resultados foram 
comparados com resultados anteriores de iELISA e reveladas sensibilidade de 99,1 por 
cento e especificidade de 99,7 por cento. 
Palavras-chave: Anticorpos monoclonais, ELISA de competição, Besnoitiose bovina, 
Besnoitia besnoiti, mAb-cELISA1
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Preface 
 
The present dissertation was written following a six-month internship, from November 
2018 to April 2019, at Institute of Epidemiology, Friedrich-Loeffler-Institut (FLI) 
Greifswald-Insel Riems, Germany.  
The work of the FLI focusses on farm animal health and welfare and on the protection of 
humans from zoonosis. The FLI does applied research in different scientific fields. 
Under the supervision and guidance of Doctor Gereon Schares, a recognized specialist in 
parasitology, the author was able to learn and practice laboratory techniques such as cell 
culture maintenance, enzyme-linked immunosorbent assay (ELISA), sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis (SDS-PAGE), Immunoblot assay, Immunoflu-
orescence assay (IFAT) and  meanwhile develop a study of mAbs characterization in 
order to develop the first mAb based competitive ELISA (Bb-cELISA1) with highly sen-
sitivity and specificity.  
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1. Literature Review  
1.1. Besnoitia besnoiti  
 
Besnoitia besnoiti is a cyst-forming obligate intracellular apicomplexan protozoan 
parasite. B. besnoiti has been placed in the Sarcocystidae family and in the 
Toxoplasmatinae subfamily along with other parasite species of medical and veterinary 
relevance, such as Toxoplasma gondii and Neospora caninum, the causative agents of 
toxoplasmosis and neosporosis, respectively (Marotel, 1912). 
 
B. besnoiti is the aetiological agent of bovine besnoitiosis, a chronic and debilitating 
disease of cattle. This disease causes morbidity and severe economic losses, mostly by 
infertility in bulls, but also by a decline in milk production and occasionally secondary 
abortions in cows and skin lesions (Pols, 1960; Bigalke, 1968). 
 
The complete life cycle of B. besnoiti remains unkown; cattle and antelopes are known 
as natural intermediate hosts of B. besnoiti but the definitive host of this parasite has not 
been identified, yet. Two different intermediate host stages are known: tachyzoites and 
bradyzoites. Most likely, this parasite needs in addition to intermediate hosts also 
definitive hosts to fulfil its probably heteroxenous life cycle with a predator as definitive 
host and a prey species as intermediate host in which cysts are formed. It has been 
suggested, that wild ruminants and rodents can possibly be considered as reservoirs of the 
parasite (European Food Safety Authority, 2010).  
 
It has been shown that Stomoxys calcitrans and Tabanidae species can act as mechanical 
vectors to transmit infection from chronically or asymptomatic infected cattle to other 
animals (Bigalke, 1968). Although low antibody levels during winter when there is no 
biting fly activity suggests that a transcutaneous infection via insects is essential, still 
more investigations are required to confirm the role of biting flies in the transmission of 
bovine besnoitiosis (Liénard et al., 2011; Sharif et al., 2019). A very present and 
concerning issue is that the global warming can promote the development of biting flies 
and cause extension of their activity period and thus may promote the transmission of B. 
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besnoiti. A further possibility of mechanical transmission is iatrogenically, during 
prophylactic or treatment procedures (Pols, 1960; Bigalke, 1968; Kutz et al., 2009). 
 
There is epidemiological evidence of direct transmission between animals, possibly via 
mucosal contact by licking (Cortes et al., 2014). The presence of cysts in the genital 
mucosae suggests that transmission during natural mating is also a possibility (Cortes et 
al., 2014; Hornok et al., 2014). In addition, the recovered and subclinically infected 
animals are considered an important source of infection since they remain lifelong carriers 
(Álvarez-García et al., 2013). There are no evidences of vertical transmission, however 
the negative impact on milk production often aﬀects the development of the calf (Cortes 
et al., 2006). 
 
B. besnoiti infection may pass through an (1) acute stage (11–24 days post infection) a 
(2) subacute stage (between the end of acute disease and the macroscopic observation of 
the first tissue cysts) and (3) the chronic stage (>34 days post infection) (Cortes et al., 
2014). The severity of the disease can vary between mild and severe with a mortality rate 
lower than 10 % (European Food Safety Authority, 2010). 
 
B. besnoiti tachyzoites rapidly proliferate in macrophages, ﬁbroblasts and endothelial 
cells in blood vessels and are responsible for the acute stage of the disease (Schulz, 1960; 
Cortes et al., 2005). Chronic besnoitiosis refers to the stage in which B. besnoiti 
tachyzoites switch into slowly dividing bradyzoites (cystozoites), which are contained in 
thick walled tissue cysts mainly found in the cutis, subcutis, fascia, conjunctiva, and the 
genital and respiratory mucosa (Bigalke, 1968). 
 
1.2. Introduction of Bovine besnoitiosis 
 
Bovine besnoitiosis has been described in the sub-Sahara Africa (Bigalke & Prozesky, 
2004) and Asia (Olias et al., 2011). In the past decades, several outbreaks in Portugal 
(Cortes et al., 2004; 2005; 2006), France (Alzieu et al., 2007; Jacquiet et al., 2010; Liénard 
et al., 2011), Germany (Schares et al., 2009; Rostaher et al., 2010)), Spain (Juste et al., 
1990; Fernández-García et al., 2009; 2010; Gutiérrez-Expósito et al., 2013), Croatia 
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(Beck et al., 2013), Hungary (Hornok et al., 2014), Italy (Gazzonis et al., 2007; 2014; 
Gentile et al., 2012), Switzerland (Basso et al., 2013) and Belgium (Vanhoudt et al., 2015) 
have been reported. Since 2010 bovine besnoitiosis is considered a re-emerging disease 
and endemic in Europe according to the European Food Safety Authority (EFSA) and 
there is evidence of an increased number of cases and geographic expansion of the B. 
besnoiti infection and the associated disease. More recently in 2016, besnoitiosis was 
diagnosed in an Irish dairy herd, it was the first outbreak in Ireland or the United Kingdom 
and the most northern European outbreak described, yet (Ryan et al., 2016).  
 
Bovine besnoitiosis can affect all cattle breeds, animals of all ages and both sexes, 
however the clinical disease is quite unlikely to affect calves of less than six months old 
(Bigalke, 1968). 
 
At the acute phase is characterized by nonspecific signs that make clinical diagnoses 
difficult: hyperthermia (above 40°C), tachycardia, tachypnea, serous nasal and ocular 
discharges, anorexia, weight loss, generalized weakness, superficial adenomegaly, 
anasarca of a variable degree with joints edema that may cause pain during movement 
and lead to lameness, loss of milk production, acute orchitis and painful testes (Schulz, 
1960). Differential diagnoses include infectious bovine rhinotracheitis (IBR), bluetongue 
virus, malignant catarrhal fever and Mycoplasma bovis infection (Ryan et al., 2016). 
 
During chronic disease the dermal lesions are always present making a diagnosis based 
on clinical signs easier when compared with the acute phase. Dramatic thickening, 
hardening and folding or wrinkling of the skin, always accompanied by hyperkeratosis, 
hyperpigmentation and alopecia are visible (Figure 1); bulls can develop necrotizing 
orchitis, which may result in permanent infertility (Pols,1960). Differential diagnosis 
include photosensitization, ringworm, scabies, trace element deficiencies and cutaneous 
lymphoma (Cortes et al., 2014). 
 
We can define three clinical classes after infection by B. besnoiti: (1) a small proportion 
of animals developing typical clinical signs, (2) a group of seropositive animals with 
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sclero-conjunctival cysts and (3) the largest group, i.e. a group of seropositive but 
asymptomatic animals (Pols, 1960). 
 
 
Figure 1 - A case of besnotiosis in a cow presenting severe besnoitiosis skin lesions 
(Adapted from Cortes et al., 2006) 
 
1.2.1.  Diagnostic methods 
 
Several techniques have been reported for the diagnosis of bovine infection with B. 
besnoiti, these include direct detection of the parasite (the presence of cysts on the 
conjunctiva and vulva) and/or its deoxyribonucleic acid (DNA) in tissue samples 
(histopathology and polymerase chain reaction (PCR)) and indirect detection based on 
serology (iELISA, IFAT and Immunoblot assay) (Cortes et al., 2014). 
 
Nowadays, in animals suffering from chronic disease the diagnosis of bovine besnoitiosis 
can be achieved by the direct detection of the parasite and/or its DNA. In this phase 
specific antibodies can be detected but not in all cases (Hemphill & Leitão, 2014). For 
the diagnosis of clinical and subclinical disease, the detection of antibodies against B. 
besnoiti in sera seems to be the most appropriate approach. 
 
After the development of tissue cysts has started, a histopathologic analysis may represent 
a good method for diagnosis, due to the very high number of cyst in the skin of sick 
 5 
 
animals. However, in cases where the cysts are absent on a histological slide of the skin, 
the overall cattle may harbour still tissue cysts in a high number (Cortes et al., 2014). It 
was recommended to examine a skin punch biopsy (8 mm diameter) from the ‘Rump’ 
region since this skin region seems to represent the optimal site for taking skin biopsies 
for detection or isolation of B. besnoiti (Schares et al., 2016).  
 
A conventional and real-time fluorescent polymerase chain reaction (“ITS1 rDNA PCR”) 
for detection of B. besnoiti infections in bovine skin biopsies have been developed by 
Cortes et al. (2007a). It was based on the sequence of the internal transcribed spacer 
region 1 (ITS-1) of the ribosomal RiboNucleic Acid (RNA) gene of B. besnoiti and have 
been used to detect the parasite in skin biopsies through the amplification of parasite 
specific DNA sequences. A real time PCR assay was also established for the quantitative 
detection of B. besnoiti in chronically infected cattle by Schares et al. (2011). This 
technique is highly sensitive and specific but, unfortunately, PCR assays are not routinely 
used in many diagnostic laboratories. 
 
Indirect ELISAs (iELISAs) available as commercialized or in-house tests can be 
recommended as fast and inexpensive mass screening test for seroepidemiological 
examinations of bovine besnoitiosis. Schares et al. (2013) have developed a method to 
detect B. besnoiti antibodies by iELISA, using a so-called “APure BbELISA antigen”, 
produced by sequential immunoaffinity chromatography, which had a diagnostic 
sensitivity of 100 % and a diagnostic specificity of 99.8 %, relative to reference tests. 
This APure BbELISA antigen can be employed with diagnostic purposes without the need 
of Immunoblot assay to confirm and have been found appropriate diagnostic techniques 
in the acute stage of the disease (García-Lunar, 2016). 
 
Immunoblot assays are frequently used as confirmatory assays to validate findings by 
other serological techniques for the diagnoses of bovine besnoitiosis. Techniques based 
in tachyzoite and bradyzoite extracts separated in SDS-PAGE under non-reduced and 
reduced conditions have shown diagnostic specificity and sensitivity values close to 100 
% (Fernández-García et al., 2009; Schares et al., 2010). However, it is an expensive and 
time-consuming tool and it is only available in some specialized laboratories. 
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A microagglutination test (MAT) developed by Waap et al. (2011, 2014) have shown to 
have a large-scale and low cost applicability. The capability for detection of antibodies, 
without the need of specific secondary antibodies, makes this technique attractive for 
wildlife studies. However, cross-reactions with similar parasites can still be seen and is 
recommended a confirmatory test. 
 
Diagnostic problems are the lack of sensitivity in the detection of antibodies mainly 
during the acute and sometimes the chronic stage, as well as a lack of serological 
specificity. There are commercial tests for which high proportions of false-positive 
reactions are reported, probably because as a consequence of the cross-reactions with 
similar parasites, e.g  N. caninum, T. gondii or Sarcocystis spp (Shkap et al., 2002; Cortes 
et al., 2006; Schares et al., 2010). This expresses problems in the differentiation of the 
diseases serologically, which is necessary in countries where more than one infection 
coexist. 
1.2.2. Control measures  
 
More than one hundred years after the first reference of the disease (Cadéac, 1884), and 
the first reference to its parasitic etiology (Besnoit and Robin, 1912) (both cited by Pols, 
1960), this parasitic disease has been persisting mysteriously. There are no efficient 
pharmaceutical compound available for the treatment of besnoitiosis in cattle and no exact 
recommendation to control it. Arylimidamides have shown some promise, sulfamides and 
tetracyclines are commonly used to diminish the severity of clinical signs, nevertheless, 
this therapeutic is not effective in vivo and relapses can happen (Cortes et al., 2007b; 
2011; Jacquiet et al., 2010). The use of attenuated live vaccines are not authorized in most 
of European countries because of the lack of scientiﬁc data that guarantee eﬃcacy and 
safety. There is a risk of introducing the parasite into uninfected herds and of inducing 
carriers among the vaccinated animals. In South Africa, the vaccine is based on 
tachyzoites of an isolate from blue wildebeest grown in cell cultures (Bigalke et al., 1974). 
In Israel, the vaccine in use contains live attenuated parasites derived from cell cultures 
(Pipano, 1997). 
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Control measures should be performed in three steps: (a) a serological analysis before 
introducing an animal into a besnoitiosis-free cattle herd, (b) a systematic evaluation of 
infection status of individual cattle in case besnoitiosis is emerging in a previously free 
herd with the aim to separate or to cull all seropositive animals, and (c) the protection of 
animals against ectoparasites (Jacquiet et al., 2010). To increase the awareness, it is worth 
promoting all the information about the disease not only to veterinarians but also to cattle 
breeders and farmers (Jacquiet et al., 2010). 
 
1.3. Monoclonal antibodies background 
Kohler and Milstein (1975) have revolutionized the regulation of immune responses with 
their vision for antibodies as tools for research on vaccine production and prevention, 
diagnostic and treatment of diseases. Because of the hybridoma technology, monoclonal 
antibodies homogeneous and highly specific are being developed against single epitopes 
and can be produced in unlimited quantities (Kohler & Milstein, 1975; 1976). 
 
Thirteen mAbs were previously produced in the Institute of Epidemiology, Friedrich-
Loeffler-Institut, Greifswald-Insel Riems, Germany, against an enriched membrane ex-
tract of B. besnoiti (APure BbELISA) that were prepared following previous procedures 
(Schares et al., 1998; Schares et al., 2013; Wouda et al., 1998). 
 
The enriched membrane extract had been labelled by surface biotinylation and analysis 
by a subsequent immunoprecipitation showed that at least some of the extracted antigens 
are located on the tachyzoite surface (Schares et al., 2013). 
 
To produce mAbs against APure BbELISA antigen two BALB/c mice were immunized 
with three subcutaneous injections of 50 µg of the ELISA antigen (enriched membrane 
extract) using GERBU MM as an adjuvant (GERBU Biotehnik GmbH, Heidelberg Ger-
many). The second and third injections were made four and eight weeks after the initial 
immunization with the same amount of the antigen preparation, for both mice. Three days 
after the last immunization, spleen cells (lymphoblasts) of Mouse 1 were fused with Sp2/0 
myeloma cells and hybridoma cells grown as described (Schares et al., 1999). Eleven 
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months after the initial immunization, Mouse 2 was injected again with 50 µg of the an-
tigen preparation, finally spleen cells (lymphoblasts) of the animal were fused with Sp2/0 
myeloma cells. The euthanasia and fusion of the mouse spleen cells with SP2/0 myeloma 
cells happened three days after the last immunization. Then the hybridomas supernatants 
were screened for antibodies by immunoblot and the positive hybridomas were cloned 
and re-cloned if possible twice in order to insure their clonality (Figure. 2). 
 
 
Figure 2 - A summary of the monoclonal antibody production. (Adapted from 
https://bio.libretexts.org/Bookshelves/Microbiology/Book%3A_Microbiology_(Ope
nStax)/20%3A_Laboratory_Analysis_of_the_Immune_Response/20.1%3A_Practic
al_Applications_of_Monoclonal_and_Polyclonal_Antibodies?fbclid=IwAR3M-0 
348DHY792lZ_gT3Be7YCFwrZwWNpbvRdPVaIrPNNohHw0pBedeOM, 
consulted at September 2019) 
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The mouse experiments reported in this publication were approved by the “Landesamt 
für Landwirtschaft, Lebensmittelsicherheit und Fischerei” of the German Federal State of 
Mecklenburg-Vorpommern (Permit 7221.3-2.5-004/10). 
 
Isotyping was performed with a commercially available kit called “IsoQuickTM Strips and 
Kits for Mouse Monoclonal Isotyping” (Sigma-Aldrich, Deisenhofen, Germany), in order 
to characterize the mAbs by their immunoglobulin class and subclass (heavy chain) and 
light chains. The results are expressed in Table 1. 
 
Table 1 - Isotyping results of mAbs 
 
 
Of the thirteen hybridomas, nine produced Imunoglobulin (Ig) G1 antibody (Ab) and 
three produced IgG2 Ab. MAb 1 produced both IgG1 and IgG2 which suggests that 
hybridoma cells were not clonal, yet. 
 
Regarding the light chain isotype, all thirteen hybridomas produced kappa Ab. 
Most of the monoclonal antibodies were class IgG and subclass 1. That fact can be 
explained by the humoral immune response that in response to protein antigens 
mAb 
designation 
Hybridoma supernatant designa-
tion 
Heavy Chain Light Chain 
1 1/18-8/2-8 IgG1/IgG2a Kappa 
2 1.17.8 IgG2a Kappa 
3 1/24-9/9-4 IgG1 Kappa 
4 1/24-9/2-10 (B11) IgG1 Kappa 
5 1/17-7/15-3/1-3/3-13 (24-9) IgG1 Kappa 
6 B 9.2.5 IgG2a Kappa 
7 1/2-6/1-9 IgG1 Kappa 
8 7.5.5 III IgG1 Kappa 
9 9.23.11 I IgG1 Kappa 
10 B 2.5.7 IgG1 Kappa 
11 3.10.8 III IgG1 Kappa 
12 B 6.21.5 IgG2a Kappa 
13 B 5.5.11 IgG1 Kappa 
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predominantly produce IgG1 subclass, whereas polysaccharide antigens predominantly 
give rise to IgG2 antibodies; the adjuvant used can also effect the prevalence of IgG1; 
and the used myeloma parental line was maybe producing IgG1 (Köhler & Milstein, 
1975; Stevens et al., 1983; Siber et al., 1980). After isotyping, all hybridoma supernatants 
were stored at 4°C until used. 
For simplicity reasons, in this study the mAbs will be referred by the mAb designation 
and not by the hybridoma designation (Table 1).  
 
2. Statements and definition of tasks 
 
A number of serological methods have been developed to diagnose bovine besnoitiosis. 
Despite the valuable efforts made in order to find a gold standard diagnostic method, a 
specific, sensitive, rapid and economic technique has not been established yet. 
 
The accurate impact of this re-emerging disease has not been determined so far because 
of the lack of prevalence and incidence studies, therefore an efficient diagnostic method 
would contribute as well to the implementation of control strategies in the already affected 
and also on risk areas. 
 
The identification of subclinical forms are more challenging when compared with the 
identification of clinical cases, thus serology is considered an appropriate diagnostic tool. 
The identification of serologically positive animals is of major relevance to elaborate 
proper control measures as mentioned before. 
 
Clinical cases represent the iceberg's tip of besnoitiosis and are relatively sporadic. Most 
affected cattle are asymptomatic and subsequently constitute a reservoir that must be 
identified as early as possible (Bigalke, 1968; Jacquiet et al., 2010). 
 
The following sections focus on several essential techniques to achieve a characterization 
of the mAbs with the target of a mAb based cELISA (Bb-cELISA1). For this purpose, 
thirteen mAbs were characterized by iELISA and Immunoblot assay and, finally in order 
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to evaluate the sensitivity and specificity of the Bb-cELISA1, positive and negative 
reference cattle sera were analysed. 
 
This type of cELISA, (also known as inhibition ELISA) offers distinct advantages that 
overcome the limitations of diagnosis: the antibodies used are homogeneous, with 
specificity for a single epitope or a small protein region. They are also less likely to 
interact with antibodies to closely related proteins and cross-reactivity of secondary 
antibodies is eliminated.  
 
3. Materials and Methods 
 
3.1. Optimization of the Indirect ELISA  
 
Enzyme immunoassays allow the measurement of both Ab and antigen (Ag), the latter 
may comprise of an unlimited range of molecules (Kurstak, 1986).  
 
Indirect ELISA can detect specific antibodies and allows the quantification of mAbs in a 
microtiter plate coated with a specific Ag. In this study it was important to know if the 
hybridomas produced mAbs reactive with B. besnoiti tachyzoite antigen.  
 
In this assay the samples containing the antibody, i.e. hybridoma supernatants were added 
to the antigen coated plates and the binding antibodies were visualized later-on using a 
Horseradish peroxidase (HRP) conjugated secondary Ab that hydrolyzed the substrate 
(Figure 3). The amount of antigen-antibody complexes is assessed by photometric meas-
urement at 450 nm, after stopping the color reaction using sulfuric acid. The measured 
amount of color is proportional to the amount of specific antibody in the hybridoma su-
pernatant, but only in the linear range of the assay (Coligan, 1996). 
 
In this study the specificity and concentration of the HRP conjugated secondary Ab were 
optimized, with the final aim to evaluate the reactivity of the thirteen mAbs in the super-
natants from the hybridoma to B. besnoiti tachyzoite antigen. 
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Figure 3 - Indirect ELISA diagram 
 
 
3.1.1. Reagents, solutions and materials 
 
All solutions were prepared fresh except the substrate buffer. 
▪ Phosphate buffered saline with Tween20 0.05% (v/v) (PBS–T) 
▪ PBS–T with 20% horse serum: pH 7.2. Was used as sample dilution buffer and 
blocking solution. 
▪ PBS–T with 1% horse serum. 
▪ Bicarbonate buffer: weekly new 0.1 M; pH 8.3. Was used as coating buffer. 
▪ Sodium hydrogen carbonate. Was used as substrate buffer. 
▪ Hydrogen peroxide (H2O2) 30% 
▪ Tetramethyl benzidine (TMB) (Sigma-Aldrich, Taufkirchen, Germany). Was 
used as chromogenic substrate 
▪ 2M Sulfuric acid (H2SO4) 
▪ MAbs (undiluted): 1; 3; 4; 5; 7; 8; 9 and 11 on the iELISA optimization and from 
1 to 13 on the final iELISA 
▪ APure-BbELISA Ag (final concentration 200 ng/ml, 150 µl)  
▪ Peroxidase-Conjugated AffiniPure Sheep Anti-mouse IgG Fcγ Fragment Spe-
cific (Jackson ImmunoResearch Laboratories, West Grove, USA) 
▪ Peroxidase-Conjugated AffiniPure Rabbit Anti-mouse IgG + IgM (H+L) (Jack-
son ImmunoResearch Laboratories, West Grove, USA) 
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▪ As negative control (NC) was used Dulbecco’s Modified Eagle’s Medium 
(DMEM) and as positive control (PC) was used the fusion supernatant that was 
collected from the fused cells one to three days after fusion, both undiluted. 
▪ Nunc-Immuno™ MicroWell™ 96 well solid plates (Nunc-Immuno (Polisorb), 
Thermo scientific, Langenselbold, Germany)  
▪ ELISA reader (Tecan Sunrise, Tecan, Crailsheim, Germany) 
 
3.1.2. Execution  
 
To establish the optimal dilution of the HRP conjugated secondary Ab, the APure-
BbELISA Ag stock was briefly centrifuged and diluted in the coating buffer at a dilution 
of 1:600 and used to sensitize a 96-well microtiter plate at 37°C for one hour. The wells 
were washed three times with PBS–T and the unbound active sites were blocked with 
PBS–T, 20% horse serum, followed incubation at 37°C. After 30 minutes (min), some 
mAbs, PC and NC sera were added and incubated again for 30 min.  The unbound anti-
body was washed away three times with PBS-T and the wells were then incubated for 30 
min with Peroxidase-Conjugated AffiniPure Rabbit Anti-mouse IgG (H+L) comparing 
two different dilutions (1:500 and 1:5000) in PBS–T, 1% horse serum. Unbound HRP 
conjugated Ab was washed away three times and the substrate solution was added (100 
µl TMB and 1.2µl H2O2 30% in 10 ml of substrate buffer). Color development was 
stopped, after 15 min, by the addition of sulfuric acid 2M 50μl /well. Optical density (OD) 
was measured at 450 nm by the ELISA reader. 
 
The test results were normalized and, for each well the index value (Iv) was calculated 
(Iv = (OD-NC) / (PC-NC)), where OD is the optical density obtained in each well, PC is 
the optical density of the positive control and NC the optical density of the negative con-
trol). The results are in Table 5 (in the “Results” chapter of this study). 
 
With the establishment of the optimal dilution of the HRP conjugated Ab, the selection 
of the optimal HRP conjugated Ab regarding the specificity was followed. The protocol 
was similar with the exception that, it was performed comparing two different HRP con-
jugated Ab: Peroxidase-Conjugated AffiniPure Rabbit Anti-mouse IgG (H+L) and Pe-
roxidase-Conjugated AffiniPure Sheep Anti-mouse IgG Fcγ Fragment Specific, both at 
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the dilution of 1:500 in PBS–T with 1% horse serum. The test results were normalized 
and interpreted as mentioned above and are expressed in Table 6 (in the “Results” chapter 
of this study). 
 
Finally, an iELISA was performed with all the supernatants of the hybridoma in optimal 
conditions. The protocol was performed as mentioned above with the optimal conditions 
of the HRP conjugated Ab: Peroxidase-Conjugated AffiniPure Sheep Anti-mouse IgG 
Fcγ Fragment Specific at the dilution of 1:500 in PBS–T, 1% horse serum. 
 
3.2. SDS-PAGE and Western blotting 
 
The aim of the present study was the definition of the specificity and reactivity of each 
mAb. For that purpose we performed SDS-PAGE and Western blot analyses of several 
B. besnoiti, T. gondii and N. caninum antigens, to analyze in Immunoblot the reaction of 
the mAbs. 
We used Polyvinylidene difluoride (PVDF) membranes with blotted antigens of B. 
besnoiti tachyzoites, B. besnoiti bradyzoites and APure-BbELISA Ag. Because of the 
possible cross-reactions of Besnoitia antisera with N. caninum and T. gondii antigens we 
analyzed also the reaction of the mAbs to the membranes of N. caninum tachyzoites and 
T. gondii tachyzoites.  
The SDS-PAGE (Lämmli, 1970) combines the high-resolution power of the electropho-
retic mobility of the respective proteins in a polyacrylamide gel with the capability of 
sodium dodecyl sulfate (SDS), an anionic detergent, to break down protein aggregates 
into their individual polypeptide chains and charges them negatively. SDS-PAGE and the 
subsequent Western blotting has become a standard tool in every laboratory in which 
proteins are analyzed and purified (Towbin et al., 1979). 
The first step is the preparation of the gels, running the gel electrophoresis which was 
followed by the protein electrophoretic transfer from the SDS-PAGE to PVDF mem-
branes using a semidry Western blot transfer system. The method used in the laboratory 
based on a protocol developed by Towbin et al. (1979).  
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SDS-PAGE was carried out using 12.5 % polyacrylamide gels. All Ag based on entire 
zoites had either been obtained by cell cultivation or by collecting from heavily infected 
skin (in the case of B. besnoiti bradyzoites). Tachyzoites pellets were conserved at -80°C 
and bradyzoites (tissues) were conserved at -20 ºC; they were diluted in both reducing and 
non-reducing sample buffer. For reducing conditions beta-mercaptoethanol (βME) was 
added to the sample buffer to reduce the disulphide bridges of proteins, so they can be 
better separated by size in SDS-PAGE gels. However, certain antibodies cannot detect 
proteins in their reduced forms and in that case we also needed to perform SDS-PAGE 
under non-reducing conditions, which means not using βME in the sample buffer. For 
both reducing and non-reducing conditions, samples of 100 µl containing 4 x 108 B. 
besnoiti tachyzoites, 4 x 107 T. gondii tachyzoites, 4 x 107 B. besnoiti bradyzoites, 8 x 107 
N. caninum tachyzoites, and 85 µg of APure-BbELISA Ag were used for the production 
of each gel. 
 
3.2.1. Reagents, solutions and materials 
 
▪ Solution A (collection buffer): 6.06 g Tris-Hydrochloride (HCl), 4 ml 10% SDS, 
fill up 100 ml bidistilled water; pH 6.8 
▪ Solution B (running buffer): 18.17 g Tris-HCl, 4 ml of 10% SDS, fill up 100 ml 
bidistilled water; pH 8.8 
▪ Solution C (acrylamid): 30 ml Acrylamid, 0.80 g N,N`-Methylen-bis-acrylamid. 
Fill up 100 ml bidistilled water  
▪ Tetramethylethylenediamine (TEMED) 
▪ Ammonium Persulfate (APS) 40% (w/v).  
▪ Antigen: All tachyzoites were grown in Marc-145 cell (rhesus monkey (Macaca 
mulatta), foetal kidney cells, permanent) monolayers with DMEM supplemented 
with 5% fetal calf serum (FCS) and 1% Penicilin/Streptomycin (Biochrom, Ber-
lin, Germany) maintained at 37 °C/5% carbon dioxide (CO2). To use the tachyzo-
ites as Ag in serological tests, at least one day prior to harvesting, a change for 
DMEM without FCS was made to avoid that N. caninum specific antibodies fre-
quently present in FCS may cause false positive reactions (Dubey et al., 2017). 
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Tachyzoites were separated from host cells by vigorous pipetting with cold phos-
phate buffered saline (PBS) washes, filtered with 5 μm hydrophilic syringe filters 
(Sartorius Lab Instruments, Göttingen, Germany) and centrifuged for 10 min at 
974 X g at 4°C. Pellets were resuspended in PBS and the procedure was repeated 
five times. Finally, tachyzoites were counted using a Neubauer improved cell 
counting chamber (NanoEnTek Inc., Seoul, Korea) and the pellet stored at -80°C 
until used. 
The bradyzoites were mechanically released from the skin by mortar and pestle 
of an infected skin sample, washed with cold PBS five times, counted using a 
Neubauer chamber and at the end a pellet was stored at -80°C until used. 
The APure-BbELISA was produced previously by sequential immunoaffinity 
chromatography using polyclonal rabbit antisera raised against N. caninum or B. 
besnoiti by experimental infection of rabbits, coupled to rProtein A Sepharose 4B 
(Schares et al., 2013). 
▪ LMW (Low Molecular Weight) marker, (SERVA Eletrophoresis GmbH, Heidel-
berg, Germany): 
o Phosphorylase B    97.4 kD 
o Albumin bovine (BSA)   67.0 kD 
o Albumin egg    45.0 kD 
o Carbonic anhydrase   29.0 kD 
o Trypsin inhibitor (soybean)  21.0 kD 
o Cytochrome C   12.5 kD 
o Trypsin inhibitor (bovine lung)  6.5 kD 
▪ Non-reduced Sample buffer 5x: 3.75 g Tris, 10 g SDS, 35 ml Glycine, 25 mg 
Bromophenol Blue; 100 ml water; pH 6.8 adjusted with HCl 
▪ Reduced Sample buffer 5x: 3.75 g Tris, 10 g SDS, 25 ml βME, 35 ml Glycine, 25 
mg Bromophenol Blue, 100 ml water; pH 6.8 adjusted with HCl 
▪ Running buffer 5x: Tris 15 g, Glycine 72 g, SDS 5 g 
▪ PVDF membranes (Immobilon-P, Millipore, Darmstadt, Germany) - 1x / gel; 7.2x 
8.5cm 
▪ Methanol 
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▪ 1x Towbin buffer: 25 mM Tris, 192 mM Glycin, 10% Methanol, 0,1% SDS; pH 
8,3 
▪ PBS–TG (blocking solution): PBS 0.05% (v/v), Tween20 2% (v/v), fish gelatine 
liquid (Serva, Heidelberg, Germany) 
▪ India Ink staining solution for PVDF membranes: 5 ml concentrated acetic acid, 
0.5 ml fountain pens (Pelikan); 500 ml PBS-T 
▪ Filter paper (Hahnemühle FineArt, Dassel, Germany) - 7.5 x 8.5cm 
▪ "Trans-Blot Turbo" equipment (Bio-Rad laboratories, California, EUA) 
▪ ThermoMixer (Eppendorf, Hamburg, Germany) 
 
3.2.2. Execution  
 
The running gel is prepared for two gels at a time because of the fast polymerization 
(description in Table 2) and added approximately five ml between the glasses, above is 
covered with bidistilled water and the polymerization lasts one hour. After the collection 
gel is prepared (description in Table 2) and added above, the comb is carefully inserted. 
 
Table 2 - Running gel and collection gel – Volume of solutions for the preparation 
of SDS-PAGE gels 
 
Running gel – volume for 2 gels  Collection gel – volume for 4 gels 
Solution B (ml) 2.5  Solution A (ml) 1.5 
Solution C (ml) 4.2  Solution C (ml) 0.7 
Bidest water (ml) 3.3  Bidest water (ml) 3.6 
Total (ml) 10  Total (ml) 5.8 
10.0 µl of TEMED and 25.0 µl of APS 
40% are added 
16.0µl of TEMED and 8.0 µl of APS 
40% are added 
 
 
Thereafter, the Ag is diluted in 1x sample buffer (reduced and non-reduced) and incubated 
for 10 min at 95°C in the ThermoMixer. Then the BIO-RAD chamber is filled in with 1x 
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running buffer and the Ag is added to the preparative slot (usually 100 µl) as well as the 
marker (5 µl) which is added into a separate small slot. The electrophoresis is performed 
at 120 V, 500 mA, 150 W for approximately one hour and 20 min. 
 
The PVDF membrane are activated in methanol and then placed in 1x Towbin buffer and 
shaken. The filter and the gel are placed in the 1x Towbin buffer. Methanol is known to 
improve the adsorption of protein to the membrane support, prevent gel swelling, and 
protein distortion during electroblotting (Towbin & Gordon, 1984). 
The blotting sandwich is composed by three filters, one PVDF membrane, one gel and 
above more three filters, care was taken to remove all air bubbles. The blot sandwich is 
placed in "Trans-Blot Turbo" equipment and the semi-dry electro blotting is performed 
at 25 volts/gel for 30 min. 
 
After the transfer two strips of the membrane, coated with the marker proteins and the 
antigen, were cut off and the transferred proteins visualized using an India ink stain to 
check the effectiveness and homogeneity of the transfer across the membrane, as 
previously reported (Hancock & Tsang, 1983). 
 
Finally, it is important to block the remaining binding sites by immersing the membrane 
in a blocking solution. Blocking a blot serves two important purposes: help mask any 
potential nonspecific binding sites on the membrane itself and promote renaturation of 
antigenic sites (Towbin & Gordon, 1984). 
When dry, the membrane and respective inked strips can be properly stored at -20°C. 
 
3.3. Immunoblot assay 
 
We analyzed the reaction of the mAbs to PVDF membranes containing total lysates of B. 
besnoiti tachyzoites and bradyzoites, as well as APure-BbELISA Ag. To detect cross-
reactions we analyze the reaction of the mAbs to membranes with total lysate antigens 
from N. caninum tachyzoites and T. gondii tachyzoites. Those procedures were carried 
out with the Immunoblot assay under reducing and non-reducing conditions. 
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After SDS-PAGE the transferred proteins were bound to the surface of the membrane, 
providing access to immunodetection by specific mAbs. Any remaining binding sites 
were blocked by immersing the membrane in a blocking solution. After probing with the 
mAbs (primary Ab) the antibody-antigen complexes were detected using the HRP conju-
gated (secondary ab) and 4-chloro-1-naphthol as a substrate.  
In this assay the mAbs were applied undiluted. The used control sera were diluted at 1:100 
in PBS–TG and are described in table 3.  
 
3.3.1. Reagent, solutions and materials 
 
• PBS–TG: PBS 0.05% (v/v), Tween20 2% (v/v), fish gelatine liquid. Used as 
blocking solution and buffer. 
• Tris-buffered saline (TBS); pH 7.4. Used for washing and buffer. 
• TBS-T (0.05%): TBS, Tween 20 0.05%; pH 7.4. This buffer was used for wash-
ing. 
• HRP conjugated secondary Ab: Peroxidase-conjugated AffiniPure sheep Anti-
mouse IgG Fcγ Fragment Specific 1:500 diluted in PBS–TG. 
• mAbs.  
• Substrate solution: 40 ml TBS, 40 μl H2O2 30% (v/v), 30 mg 4-chloro-1-naphthol 
[Sigma] in 10 ml methanol. 
•  PVDF membranes containing: B. besnoiti tachyzoites, B. besnoiti bradyzoites, N. 
caninum tachyzoites, T. gondii tachyzoites and APure-BbELISA Ag.  
• Positive control and negative control (Table 3) 
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Table 3 - Controls used for each PVDF membrane in Immunoblot assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2. Execution 
 
The strips were firstly wetted in PBS–TG and then the mAbs, the Positive control and the 
Negative control were added. After the strips were shacked for one hour and the solution 
removed, they were washed five times with TBS-Tween (0.05%). The HRP conjugated 
secondary Ab was added to incubate, then the solution was removed and the strips washed 
three times with TBS-Tween (0.05%) and two times with TBS. 
Finally, the substrate solution was added to the strips. The reaction was stopped after 
aspirating the substrate solution and after a final wash with double-distilled water was 
made. 
 
3.4. Meta-periodate treatment 
MAbs were developed against the enriched membrane extract of B. besnoiti tachyzoites. 
For the characterization of mAbs we tried to determine if they are recognizing 
carbohydrate or protein epitopes. 
To determine the possible involvement of carbohydrates in the formation of epitopes that 
bind to the generated mAbs, a meta-periodate treatment was performed according to 
Membrane Positive control Negative control 
B. besnoiti tachyzoites B. besnoiti positive bovine 
serum. 
N. caninum posi-
tive bovine serum 
B. besnoiti bradyzoites 
APure-BbELISA Ag 
N. caninum tachyzoites N. caninum positive mouse 
serum 
DMEM 
T. gondii tachyzoites Pool from six mice T. 
gondii positive serum 
DMEM 
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Woodward et al. (1985). The meta-periodate treatment consists in a mild periodate 
oxidation at acid pH that enable the cleavage of carbohydrate vicinal hydroxyl groups 
preventing the modification of polypeptide chain structures (Woodward et al., 1985). 
This method is particularly useful in the Immunoblot assay because the modification of 
epitopes take place after electrophoretic separation of proteins eliminating the problems 
associated with changes in electrophoretic mobility which result from enzymatic and 
chemical deglycosylation procedures which are applied prior to the SDS-PAGE 
(Woodward et al., 1985). 
 
 
3.4.1. Reagents, solutions and materials 
• Natrium-Acetat-buffer: 1.361 g Na-Acetat in 100 ml water; pH 5.5 adjusted with 
acetic acid 
• Natrium-meta-Periodate-buffer: 10 mM Natrium-periodate in Natrium-acetat-
buffer; pH 5.5 adjusted with acetic acid 
• Stopping solution: 50 mM Natrium-Borohydrid in PBS 
• Nitrocellulose membrane (Optitran, Schleicher & Schuell, Dassel, Germany): 
7.2x 8.5cm 
• As Positive Control was used a B. besnoiti positive bovine serum and as Negative 
Control was used a N. caninum positive bovine serum 
  
3.4.2. Execution 
The procedure started with a preparation of a SDS-PAGE gel containing APure-
BbELISA Ag with a subsequent Western blotting. The protocol was the same mentioned 
previously in this study, except with one modification: it was important to activate the 
nitrocellulose membrane with bidistilled water instead of methanol. After the Western 
blotting, the nitrocellulose membrane was cut into 26 strips.  Subsequently, thirteen strips 
were incubated in Natrium-Acetat-buffer and another thirteen strips stayed in Natrium-
meta-periodate-buffer for one hour in the dark, at room temperature. After one hour, the 
stopping solution was added and the strips were incubated for 30 min in the dark. Finally, 
the Immunoblot assay to test the mAbs was performed with the protocol previously 
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described in this study. As PC was used a B. besnoiti positive bovine serum and as NC 
was used a N. caninum positive bovine serum. 
 
 
3.5. Optimization of the Competitive ELISA  
The final aim of this study is the development of a mAb-based competitive ELISA. For 
this purpose the selected mAbs to optimization of the assay were mAb 3 and mAb 11. 
These were the selected mAbs because they expressed high index values in iELISA and 
most importantly they revealed no cross-reactions in immunoblot assay with N. caninum 
and T. gondii PVDF membranes under reducing and non-reducing conditions.  
 
The results of the assay depends on the blocking of mAb binding to the coated Ag in the 
presence of positive sera, therefore the mAbs are evaluated for its ability to compete with 
B. besnoiti positive sera for binding to the Ag.  
 
The mAbs dilution was optimized at two-fold serial dilutions at 1:10; 1:20; 1:30 and 1:40, 
therefore four different plates were performed with both mAbs in each half of the plate. 
The PC concentration used in the four plates was optimized at two-fold serial dilutions 
from 1:2 up to 1:32,768 for each mAb. Regarding the NC, the dilution was already 
optimal and performed at two-fold always at 1:2 for each mAb. All dilutions were made 
with PBS–T, 20% horse serum. As NC a N. caninum positive bovine serum was used and 
as PC a B. besnoiti positive bovine serum was applied. 
 
3.5.1. Reagents, solutions and materials 
 
All solutions were prepared fresh except the substrate buffer. 
▪ PBS–T: PBS, 0.05% (v/v) Tween 20 
▪ PBS–T, 20% (v/v) horse serum: pH 7.2. Was used as sample buffer and blocking 
solution. 
▪ PBS–T, 1% (v/v) horse serum.  
▪ Binding buffer: weekly a new 0.1 M Bicarbonate; pH 8.3 was used as coating 
buffer   
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▪ Sodium hydrogen carbonate. Was used for substrate buffer. 
▪ H2O2,  30% (v/v) 
▪ TMB: Used as chromogenic substrate 
▪ Sulfuric acid, 2M H2SO4             
▪ MAbs (3 and 11)  
▪ APure-BbELISA Ag: Ag was diluted in bicarbonate buffer (1:600) 
▪ Peroxidase-Conjugated AffiniPure Sheep Anti-mouse IgG Fcγ Fragment Spe-
cific diluted 1:500 in PBS–T, 1% horse serum.  
 
3.5.2. Execution  
 
The protocol used was similar to the iELISA protocol but still with a few changes (Figure 
4).  
The APure-BbELISA Ag was briefly centrifuged, diluted in the coating buffer and used 
to sensitize a 96-well microtiter plate at 37°C for one hour. The wells were washed three 
times with PBS–T and the unbound active sites were blocked with PBS–T, 20% horse 
serum, followed incubation at 37°C. After 30 min the PC and NC sera, diluted in PBS–
T, 20% horse serum, were added always in two-fold. After 30 min of incubation, the 
unbound antibody was washed away three times with PBS-T and the wells were then 
incubated for 30 min with mAbs 3 and 11 at the correspondent dilution depending on the 
plate. Then the wells were washed three times with PBS-T and the wells were then incu-
bated for 30 min with HRP conjugated secondary Ab diluted at 1:500 in PBS–T, 1% horse 
serum. Unbound HRP conjugated secondary Ab was washed away three times and the 
substrate solution was added (100 µl TMB and 1.2µl H2O2 30% (v/v) in 10 ml of sub-
strate buffer). Color development was stopped, after 15 min, by the addition of sulfuric 
acid. Optical density (OD) was measured at 450 nm by the ELISA reader and analyzed 
with software for an enzyme immunoassay (Tecan Group Ltd.). We calculated the inhi-
bition relative to the negative and positive controls, therefore the ODs were converted to 
percentage inhibition (PI) values by the following formula:  
 
PI(%)  =
(OD in PC test well [1: 2 to 1: 32,768]) – (OD in PC [1: 2])
(OD in NC) − (OD in PC test well [1: 2 to 1: 32,768])
 𝑥 100 
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Figure 4 - Competitive ELISA diagram 
 
3.6. Analysis of samples by Competitive ELISA  
 
In cattle serum, Ab against B. besnoiti can be detected by virtue of their ability to block 
the binding of a mAb to the target epitope in a mAb-based competitive ELISA assay. A 
total of cattle sera (n= 948) were analyzed by Bb-cELISA1 with optimal conditions with 
the aim of evaluate the sensitivity and specificity of this test. 
 
In this analysis, reference positive and reference negative cattle sera were included. These 
sera came from four different farms and were all tested for besnoitiosis with an indirect 
ELISA (“reference test”), for some cases an additional analysis by IFAT was performed. 
One farm had clinical cases of acute and chronic neosporosis, another farm had cases of 
sarcocystiosis and two others had clinical cases of chronic besnoitiosis. 
After tested for besnoitiosis, 723 samples were selected as a reference negative population 
and 225 samples as a reference positive population. 
 
The assays were carried out with mAb 3, this mAb proved to be optimal earlier when 
diluted at 1:40. 
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As NC were used a N. caninum positive bovine serum and blocking solution. As PC was 
used a B. besnoiti positive bovine serum. The PC optimal dilution was established earlier 
to be 1:100 and 1:1000. All cattle sera analyzed were diluted 1:2 as well as the NC in 
PBS–T, 20% horse serum. All controls were done in fourfold. 
The materials and the protocol used in this analysis were exactly as described previously 
for Competitive ELISA (Figure 4). 
 
After the assay, to distinguish a positive serum of a negative serum, was done a visual 
evaluation of the plate where a besnoitiosis positive serum expressed a clear well and a 
besnoitiosis negative serum expressed a well with colour development, in case of 
uncertainty the test was repeated. 
 
A comparative analysis of the “reference test” and the Bb-cELISA1 was carried out with 
the aim to evaluate the performance of Bb-cELISA1. An statistical package was used to 
find out the optimal cutpoints using Youden’s index that is equal to sensitivity plus spec-
ificity minus one. 
4. Results 
4.1.Immunoblot assay. 
 
After SDS-PAGE and Western blotting to PVDF it was possible to visualize in Immunob-
lot the protein bands recognized by each mAb. After the proteins had been transferred to 
a nitrocellulose membrane, the involvement of carbohydrates in epitope formation could 
be assessed with a meta-periodate treatment. 
Usually, the Immunoblot assay was implemented with PVDF membranes after SDS-
PAGE had been performed under reduced and non-reduced conditions, in order to evalu-
ate the reactivity and specificity of the mAbs for different parasitic stages (B. besnoiti 
tachyzoites and B. besnoiti bradyzoites), antigen preparations (APure BbELSA Ag) or 
other species (N. caninum tachyzoites and T. gondii tachyzoites). 
After immunoblotting the relative molecular masses of the reactive bands were deter-
mined by comparison with a LMW-SDS Marker standard. The reactivity and the relative 
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molecular masses are expressed in the Table 4 and, the reactive bands are displayed in 
Figures 5, 6, 7, 8 and 9. 
To assess the involvement of carbohydrates, APure-BbELISA Ag was separated under 
non-reduced conditions in SDS-PAGE and Western blotted to a nitrocellulose membrane. 
The membrane was cut in 26 strips and thirteen control strips were incubated only with 
Natrium-Acetat-buffer (first strip of the pair) and other thirteen strips were mildly oxi-
dated with Natrium-meta-periodate-buffer (second strip of the pair). An immunoblot was 
performed and the mAbs were incubated with each pair of trips. The results are displayed 
in Figure 10. The effect of the meta-periodate treatment on the strips is presented in Table 
5. 
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Table 4 - Serological characterization of the mAbs: protein bands detected by Immunoblot assay after SDS-PAGE under reducing 
and non-reducing conditions and transfer to PVDF membranes 
Species 
B. besnoiti 
T. gondii N. caninum 
Stage (prep-
aration) 
T B T (APure-BbELISA Ag) T  T 
mAb 
rb nrb R nrb rb nrb rb nrb r nrb 
1 88.7 - - - - 87.6; 42.3 82.2 - - - 
2 - > 97.4 - - - > 97.4 - - - - 
3 42.5 > 97.4 (22.5; 21.0; 15.9) > 97.4 > 97.4 42.9 (42.1) > 97.4; 21.6; 16.8 (22.8; 
22.1) 
- - - - 
4 42.1 > 97.4 > 97.4 > 97.4 42.9 (42.1) > 97.4 - - - - 
5 - 81.7 - - - 85.5; 80.6; 70.3 (60.4; 
36.1) 
- - - - 
6 75.7 (45.0) 80.6 - - 77.1; 34.6; 30.5; 
(56.9; 20.4; 38.0) 
84.4; 80.0; 38.8; 19.6 
(74.6; 63.7; 25.9) 
43.5 - - - 
7 - 81.7 - - - 85.5; 81.1; 70.3 (60.4; 
36.1) 
- - - - 
8 40.1 (37.2; 30.6; 26.8; 
26.6) 
41.3 (39.5; 37.7; 26.8) 41.3 - 40.9 (36.0) > 97.4; 43.2; 40.1 (86.5; 
82.2; 36.1; 34.8) 
- - - - 
9 40.1 (37.2) 41.3 (39.5; 37.7) 41.7 - 40.9 > 97.4; 43.2; 40.1 (86.5; 
82.2; 37.0; 36.1; 34.8) 
- - - - 
10 40.1 (37.2; 30.6; 30.2; 
26.8; 27.2) 
41.3 (39.5; 37.7; 29.0; 
27.1) 
41.3 - 40.9 (37.2; 36.0) > 97.4; 43.2; 40.1 (86.5; 
82.2; 36.1; 34.8) 
36.4 (36.1; 
25.6) 
46.2; 44.4; 
(42.5; 40.1) 
39.8 40.2; 38.6 
(33.8) 
11 - 34.9 (39.5; 37.7) - - - 39.7; 37.9; 36.1; 33.9 - - - - 
12 33.1 (24.5) 32,7 (29.9) 33.9; 
31.9 
28.5 
(32.0) 
33.1; 30.6 33.4; 30.8 (27.6; 26.2; 
22.8) 
23.4 25.9 - 24.5 
13 - 22.5; 21.0; 15.9 - - - 21.2; 16.2 (22.5; 21.8) - - - - 
T, tachyzoite; B, bradyzoite; r, reducing conditions; nr, non-reducing conditions 
b Values in parenthesis indicate the molecular size of faint reactivity 
- No reactivity observed 
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Figure 5 - Immunoblot reactions of the mAbs against Besnoitia besnoiti tachyzoites 
after SDS-PAGE under (A) reducing and (B) non-reducing conditions and 
Western blotting to PVDF membranes 
 
 
 
 Figure 6 - Immunoblot reactions of the mAbs against Besnoitia besnoiti 
bradyzoites after SDS-PAGE under (A) reducing and (B) non-reducing conditions 
and Western blotting to PVDF membranes 
 
 29 
 
 
Figure 7 - Immunoblot reactions of the mAbs against Neospora caninum 
tachyzoites after SDS-PAGE under (A) reducing and (B) non-reducing conditions 
and Western blotting to PVDF membranes 
 
 
Figure 8 - Immunoblot reactions of the mAbs against Toxoplasma gondii 
tachyzoites after SDS-PAGE under (A) reducing and (B) non-reducing conditions 
and Western blotting to PVDF membranes 
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Figure 9 - Immunoblot reactions of the mAbs against APure-BbELISA Ag after 
SDS-PAGE under (A) reducing and (B) non-reducing conditions and Western 
blotting to PVDF membranes 
 
 
 
 
4.2. Meta-periodate treatment  
 
After the preparation of the SDS-PAGE gel containing APure-BbELISA Ag, subsequent 
Western blotting under non-reducing conditions and a transfer to nitrocellulose 
membranes were performed with a mild periodate oxidation explained earlier. The results 
are provided in Figure 10. 
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Figure 10 - Immunoblot reactions of the mAbs against APure-BbELISA Ag after 
SDS-PAGE under non-reducing conditions, transfer to nitrocellulose membranes 
and meta-periodate treatment 
 
Table 5 - Serological characterization of the mAbs: effects detected by Immunoblot 
in nitrocellulose membranes after SDS-PAGE under non-reducing conditions, 
Western blotting and meta-periodate treatment 
mAb designation 
Effect of meta-periodate treatment on 
APure-BbELISA Ag b 
1 - 
2 - 
3 21.6; 16.8 (22.8; 22.1) 
4 - 
5 - 
6 - 
7 - 
8 - 
9 - 
10 - 
11 - 
12 - 
13 21.6; 16.8 (22.8; 22.1) 
b Values in parenthesis indicate the molecular size of bands in which a reduction in reactivity 
after meta-periodate treatment was observed; 
- No effect observed 
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4.3 Optimization of the Indirect ELISA 
Firsts iELISAs were performed with a few mAbs to confirm antibody dilution and eval-
uate the optimal dilution of HRP conjugated secondary Ab. One HRP conjugated second-
ary Ab tested was Peroxidase-Conjugated AffiniPure Rabbit Anti-mouse IgG (H+L) 
which was applied in two different dilutions: 1:500 and 1:5000. The index values calcu-
lated using values obtained for positive and negative control are shown in Table 6.  
Table 6 - Indirect ELISA index values revealing the reactivity of some mAbs to the 
Apure-BbELISA Ag as determined by with Peroxidase-conjugated AffiniPure 
Rabbit Anti-mouse IgG (H+L) at two different dilutions (1:500 and 1:5000) 
 
Dilution 
mAb designation 1:500 1:5000 
1 0.113 -0.109 
3 1.153 0.686 
4 0.250 -0.041 
5 0.084 -0.055 
7 0.097 -0.114 
8 0.580 0.002 
9 0.190 -0.084 
11 0.601 0.262 
 
 
 
After identifying the optimal HRP conjugated secondary antibody dilution it was essential 
to establish the optimal HRP conjugated secondary Ab regarding the specificity for mouse 
immunoglobulins. Prior lab experience indicated that HRP conjugated anti-mouse IgG 
(H+L) also reacted with bovine IgG which would interfere with bovine IgG in 
competitive ELISA. Therefore we tested some mAbs in the iELISA with the non-specific 
HRP conjugated secondary Ab (Peroxidase-Conjugated AffiniPure Rabbit Anti-mouse 
IgG (H+L)) and with a specific HRP conjugated Ab (Peroxidase-Conjugated AffiniPure 
Sheep Anti-mouse IgG Fcγ Fragment Specific).  The index values were calculated and 
are presented in Table 7. 
 33 
 
 
 
Table 7 - Indirect ELISA index values for some mAbs representing their reactivity 
with Apure-BbELISA antigen as determined using two different peroxidase-
conjugated secondary antibodies, diluted 1:500   
 
HRP conjugated secondary Ab 
mAb 
designation 
Peroxidase-Conjugated 
AffiniPure Rabbit Anti-
mouse IgG (H+L) 
Peroxidase-Conjugated 
AffiniPure Sheep Anti-
mouse IgG Fcγ Fragment 
Specific 
1 0.113 0.503 
3 1.153 1.016 
4 0.250 0.122 
5 0.084 0.053 
7 0.097 0.035 
8 0.580 0.410 
9 0.190 0.154 
11 0.601 0.845 
 
 
The optimal assay conditions established resulted in increased test sensitivity for the 
purpose of the study so all thirteen mAbs were finally analyzed through iELISA and Index 
Values were calculated and shown in Table 8. 
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Table 8 - Indirect ELISA index values for individual mAbs tested with the 
Peroxidase- Conjugated AffiniPure Sheep Anti-mouse IgG Fcγ Fragment Specific 
at 1:500 dilution  
 
mAb designation iELISA Index 
Values 
1 0.503 
2 0.118 
3 1.016 
4 0.122 
5 0.053 
6 0.012 
7 0.035 
8 0.410 
9 0.154 
10 0.479 
11 0.845 
12 0.019 
13 0.670 
 
4.4. Optimization of the Competitive ELISA 
 
After analyzing the mAbs in the indirect ELISA we were able to conclude that the mAbs 
3 and 11 were the ones that showed the strongest reactivity with the APure-BbELISA Ag. 
Both mAbs were used to optimize the conditions of the cELISA. 
To determine the optimal mAb and its concentration required for an optimal cELISA, 
four different dilutions were tested: 1:10; 1:20; 1:30; 1:40 in four different plates. In ad-
dition, the performance of competitive ELISAs and optimal dilutions of the Positive Con-
trol were assessed by a serial titration from 1:2 up to 1:32,768. 
For each PC titer, the percentage of inhibition was calculated and normalized by OD val-
ues of negative and positive controls, the inhibition curves were determined for the four 
different mAb dilutions (1:10; 1:20; 1:30; 1:40) for mAb 3 (Figure 11) and for mAb 11 
(Figure 12).  
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Figure 11 - Inhibitive curves as determined by a titration of the positive control 
serum and after using four different dilutions of the mAb 3 in the competitive 
ELISA using Apure-BbELISA antigen to sensitize plates.  
 
 
Figure 12 - Inhibitive curves as determined by a titration of the positive control 
serum and after using four different dilutions of the mAb 11 in the competitive 
ELISA using Apure-BbELISA antigen to sensitize plates  
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The dilution of the mAb preparation (hybridoma supernatant) had only a limited effect 
on the outcome of the competitive ELISAs. To save mAb preparation, it was decided to 
use a 1:40 dilution as optimal for the establishment of the competitive ELISA. In case of 
mAb 3 the positive serum could be diluted much higher than in case mAb 11 used in 
competitive ELISA. Based at the outcome of the titration experiments the Positive Con-
trol serum was used at 1:100 and used for the normalization of results. An additional 
1:1000 diluted control was applied in each assay as a weak positive control. These deter-
minations were essential to proceed to the next step of analysis of cattle sera. 
  
4.5. Analysis of samples by Competitive ELISA  
 
A total of 948 cattle sera confirmed to be B. besnoiti positive or negative by iELISA were 
used. These sera had been collected from four different farms (i.e. a farm with acute 
chronic cases of N. caninum infections, a farm with a sarcocystiosis problem and two 
farms with cases of chronic besnoitiosis). All sera had been tested by iELISA, previously. 
Sera from herds with neosporosis and sarcocystosis as well as B. besnoiti negative sera 
from herds with bovine besnoitiosis were regarded as “reference negative”. The B. 
besnoiti positive sera were selected from animals present in a herd with bovine besnoi-
tiosis and regarded as “reference positive”. 
 A comparative analysis of the results from the “reference test” and Bb-cELISA1 was 
carried out to achieve an accurate assess to the sensitivity and specificity of the diagnostic 
test (Table 9). 
Table 9 - Comparison of results obtained between 948 reference negative and 
positive cattle sera  
  
Reference negative sera Reference positive sera Total 
Negative 722 2 724 
Positive 1 223 224 
Total 723 225 948 
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To summarize the performance of the Bb-cELISA1, R, version 3.5.3 (R Foundation for 
Statistical Computing, Vienna, Austria; http://www.R-project.org) was used to define an 
optimal cut-off and to determine diagnostic sensitivity, specificity, and positive and neg-
ative predictive values (package “optimal.cutpoints”). 
Youden's index was used to estimate with a confidence interval of 95%: the inhibition 
cut-off was 49%, resulting in sensitivity of 99.1% and specificity of 99.9%; the positive 
predictive value was 99.6 % and the negative predictive value was 99.7%; there was only 
one false positive and two false negative results (table 10). 
In Figure 13 are expressed the inhibition percentages of the negative cattle sera (n= 224) 
and the inhibition percentages of the positive cattle sera (n=724) in the Bb-cELISA1.  
Table 10 - Optimal cutpoins with an inhibition cut-off of 49% 
 
Inhibition cut-off 49% 
Sensitivity 99.1% 
Specificity 99.9% 
Negative Predictive Value 99.7% 
Positive Predictive Value 99.6% 
False Positive 1 
False Negative 2 
 
 
The competitive ELISA Bb-cELISA1 almost perfectly separates negative and positive 
reference sera when 49% was used as the cut-off. In Figure 13 we can see that most of 
the positive reference sera showed a percentage of inhibition close to 100%. In contrast, 
most of the negative reference sera showed percentage of inhibition values around 15%. 
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Figure 13 - Distribution of inhibition percentages in Bb-cELISA1 of 224 B. besnoiti 
negative sera (on the left) and 724 B. besnoiti positive sera (on the right) against 
mAb 3 
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Discussion 
 
Although the mortality rate due to infections with B. besnoiti is low, the morbidity reaches 
10% of the herd in the first three years and, diseased males are unfertile, thus having a 
relevant economic importance and, remaining a lack of knowledge on it epidemiology. 
Thus, there is a major necessity to develop specific research programs in epidemiology, 
diagnosis and control as well. Bovine besnoitiosis can have massive effects both during 
the acute and chronic phases of infection, that can compromise the welfare of the infected 
animal.  
 
Essentially, the economic losses occur because the hides of chronically infected animals 
may become valueless for tanning, the carcasses may need to be condemned in the 
slaughterhouse, diseased bulls become sterile, milk production is insufficient, and cows, 
when pregnant, abort during the acute infection. 
 
Despite more than 100 years from the recognition of bovine besnoitiosis and research, 
some aspects related to prevalence and incidence of infection in endemic areas, routes of 
transmission and risk factors associated with the infection, remain uncertain. Serological 
tests are the key for the implementation and monitoring success of control programs and, 
the most widely used approach relies on clinical inspection and diagnostic analysis.   
The mAb technology has been improving significantly the diagnosis of protozoal and 
parasitic diseases since the limitations of polyclonal antibodies are overcome (Siddiqui, 
2010). Because of the exquisite specificity of monoclonal antibodies, highly specific 
diagnostic methods may be developed.  
 
This study was initiated in order to meet the needs of a specific and sensitive serological 
diagnostic method and the lack of epidemiologic studies that would be essential to control 
this re-emerging disease and prevent the spread of bovine besnoitiosis, nationally and 
internationally. 
 
In the present thesis, we characterized thirteen mAbs that were previously generated 
against an enriched membrane extract of B. besnoiti tachyzoites (the so-called APure-
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BbELISA Ag) in order to develop the first mAb-based competitive ELISA (Bb-
cELISA1). This aim was successfully accomplished. 
 
In order to establish an indirect ELISA to assess the reactivity of mAbs against APure-
BbELISA Ag, some mAbs were analyzed with different HRP conjugated secondary Abs 
at different dilutions. The results showed that mAbs are more reactive with APure-
BbELISA Ag, when the indirect ELISA was performed with a conjugate dilution of 1:500 
(Table 7) but regarding the type or specificity of the HRP conjugated secondary Ab (i.e. 
either a H+L or a Fcγ specificity) no marked differences were noted on the results with 
the tested mAbs (Table 8). As an optimal HRP conjugated secondary Ab, we decided to 
select the Peroxidase-conjugated AffiniPure Sheep Anti-mouse IgG Fcγ fragment 
specific secondary antibody because its specificity for the mouse IgG Fcγ fragment 
ensured minimal cross reactivity, with bovine and horse serum proteins either, used as 
analyte (bovine serum) or used as blocking reagent (horse serum) in the assay. Therefore, 
the ability of mAbs to bind the APure-BbELISA Ag was evaluated by the optimal Indirect 
ELISA established and, mAbs 3 and 11 showed relatively high Index Values of 1.016 and 
0.845, respectively. We concluded that these mAbs were the most reactive and for the 
purpose of this study they were selected to be appropriate ones to optimize the conditions 
for a competitive ELISA. 
 
To study the mAb reactivity and specificity of these and the remaining mAbs in more 
detail, several immunoblot assays were performed. Some Ags were transferred to PVDF 
membranes in both reducing and non-reducing conditions in order to evaluate specificity 
of the mAbs regarding the stage (B. besnoiti tachyzoites and B. besnoiti bradyzoites) and 
regarding the genus (T. gondii tachyzoites and N. caninum tachyzoites). It was decided to 
use also non-reduced B. besnoiti antigens because a reducing buffer (containing β-
mercaptoethanol) in SDS-PAGE destroys disulphide bonds and potentially relevant 
epitopes in both B. besnoiti tachyzoites and bradyzoites (Schares et al., 2010). Our results 
indicate that this decision was important, because, in general, relevant differences on the 
reactivity and localization of protein bands were observed between reduced and non-
reduced conditions. 
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In order to evaluate the reactivity of the mAbs, an Immunoblot assay was performed in 
both, reducing and non-reducing conditions. The PVDF membrane containing the APure-
BbELISA Ag that was used to immunize the mouse prior to mAbs production. According 
to the protein bands visualized, results showed that all thirteen mAbs reacted positively 
with APure-BbELISA Ag. However, marked differences were visualized when the Ag 
was reduced by βME (i.e. denatured and disulfide bonds were broken). Interestingly, 
overall the mAbs bound more frequently when disulfide bonds are intact (i.e., when the 
APure-BbELISA ag was used under non-reduced conditions). 
Although the mouse used for mAb production had been immunized against an enriched 
membrane extract of tachyzoites (APure-BbELISA Ag), a few mAbs reacted also with B. 
besnoiti bradyzoite antigen (mAbs 3, 4, 8, 9, 10 and 12): mAbs 3, 4 and 12 showed strong 
reactions with B. besnoiti bradyzoite antigens under both conditions, reduced and non-
reduced. A possible explanation is that some tachyzoite antigens or their epitopes are 
shared with those of the bradyzoite stage of B. besnoiti. This hypothesis was already 
mentioned by Schares et al (2013) and such cross-reacting epitopes have been previously 
reported for T. gondii (Darcy et al., 1990). 
In both reducing and non-reducing conditions, our immunoblot results showed that mAbs 
1, 2, 5, 6, 7, 11 and 13 reacted with B. besnoiti tachyzoites extracts and not with B. besnoiti 
bradyzoite antigens, which suggested that these mAbs are putative markers for 
monitoring a tachyzoite-to-bradyzoite stage conversion.  
MAbs 3 and 4 recognized a band with a molecular mass of approximately 42 kDa under 
reduced conditions in both the total B. besnoiti tachyzoites and the APure-BbELISA Ag 
extract. One of the proteins with a corresponding relative molecular weight had 
previously been identified as a surface protein by surface biotinylation of tachyzoites 
(Schares et al., 2013). Whether the proteins identified here by mAbs 3 and 4 are indeed 
located at the surface needs further clarification. Because this protein band was not 
visualized under non-reduced conditions the result may suggest that this epitope is not 
available to bind to these mAbs when the disulphide bonds are intact (non-reduced 
conditions). 
The mAbs 8, 9 and 10 reacted with a band with a molecular mass of approximately 41.3 
kDa under non-reduced conditions in B. besnoiti tachyzoites and with a protein of 
approximately 40.1 kDa under reduced conditions in B. besnoiti tachyzoites and under 
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non-reduced conditions in the membrane extract (i.e. the APure-BbELISA antigen) which 
may indicate that this protein band also corresponds to a surface protein previously 
described (Schares et al., 2013).  In this band, epitope binding seems to be not related to 
the presence of disulfide bonds in the protein band as reaction was present in both, 
reducing and non-reducing conditions.  
In some of the bands recognized by mAbs in B. besnoiti bradyzoites, a high relative 
molecular mass (> 97.4 kDa) was observed, in both reduced and non-reducing conditions 
(mAbs 3 and 4). In contrast, in B. besnoiti tachyzoites antigen such bands (>97.4 kDa) 
were visible only in non-reduced conditions (mAbs 2, 3 and 4). The same was true if the 
APure-BbELISA Ag was examined, as only under non-reduced conditions bands > 97.4 
could be visualized (mAbs 2, 3, 4, 8, 9 and 10). This could suggest that disulfide bonds 
are involved either in epitope building or in a multimerization of proteins.  
In general, no major differences were observed after the meta-periodate treatment 
suggesting that the majority of epitopes recognized by the mAbs were not related to a 
glycoprotein. However, the bands that showed significant differences after the meta-
periodate treatment were those recognized by mAbs 1, 3 and 13. These results suggest, 
that there is an involvement of carbohydrates in the formation of epitopes that bind to 
these mAbs. Regarding mAbs 3 and 13, both seemed to react with the same protein bands 
in the nitrocellulose membrane (bands of 21.6, 16.8, 22.8, and 22.1 kDa) and, in both the 
reactivity was similar after the meta-periodate treatment, showing a faint reaction 
regarding proteins with a molecular mass of 22.8 kDa and 22.1 kDa but persisting strong 
reactions with 16.8 kDa and 21.6 kDa. 
Surprisingly, mAb 1 reacted much stronger with APure-BbELISA Ag on the 
nitrocelullose membrane as compared to the reaction on PVDF membrane resulting in a 
diffuse banding pattern in case of nitrocellulose. MAbs 5 and 6 reacted differently in the 
nitrocelullose membrane lacking one protein band of high molecular weight (>94.4 kDa). 
Possibly, these differences can be explained by differences in the binding characteristics 
between nitrocellulose and PVDF membranes. 
 
As the aim was the development of a specific test, the study of cross-reactions with other 
taxonomically related coccidian parasites was crucial, therefore PVDF membranes of T. 
gondii tachyzoites and N. caninum tachyzoites were analyzed and the results showed that 
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mAbs 1, 6 and 12 reacted with T. gondii tachyzoites and mAb 10 reacted strongly with 
both T. gondii tachyzoites and N. caninum tachyzoites. The observed reactions on the 
PVDF membranes by mAb 6 and 12 were very faint and, not considered significant. After 
these results we can conclude that none of the mAbs 1, 6 or 12 would be specific to detect 
Abs against B. besnoiti in animal serum. As mAbs 3 and 11 were the most reactive to 
APure-BbELISA Ag, they were selected to be ideal for the optimization of a competitive 
ELISA. This decision was further confirmed taking into consideration the absence of 
cross-reactions with T. gondii tachyzoites and N. caninum tachyzoites membranes in 
immunoblot. 
 
The competitive ELISA to detect antibody reactions by using a specific monoclonal 
antibody as competitor largely relies on its affinity for the epitope (i.e. the antigenic 
determinant) and its specificity. The optimization of the conditions under which the mAbs 
were used in cELISA was essential in this study. In fact, the ability of mAbs to compete 
with bovine serum antibodies depends not only on the specificity and the avidity of their 
binding to the antigen but also on the relative amounts of the competing antibodies (i.e. 
mouse vs. bovine antibody concentration). Thus, mAbs 3 and 11 were tested separately 
at different dilutions with sequentially dilutions of the bovine positive control serum (1:2 
up to 1:32,768). As expected, the results showed that as much as we diluted the positive 
control, i.e. a lower concentration of epitope specific bovine serum antibodies caused a 
lower inhibition. In the case of mAb 3 a dilution of 1:1000 of the bovine positive control 
was still able to efficiently inhibit the mAb (with a percentage of about 80%). In contrast, 
in the case of the mAb 11 a dilution of 1:1000 of the bovine positive control was inhibiting 
the mAb reaction for less than 10 %.  It can be concluded that the binding of mAb 11 to 
its epitope is stronger than of mAb 3. In order to optimize the test in terms of sensitivity, 
we selected mAb 3 to establish the Bb-cELISA1. In this test, the positive control serum 
was used at dilutions of 1:100 on each plate to normalize the results. In addition, the 
positive control was also used at a dilution of 1:1000, to confirm the analytic sensitivity 
of the test on each ELISA plate. Surprisingly, it was noticed that different mAbs dilutions 
did not show a significant variation of inhibition curves (Fig. 11 and 12). Therefore, it 
was decided to use mAb 3 at the dilution of 1:40, to save as much of the hybridoma 
supernatant. 
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In order to ascertain that the Bb-cELISA1 can effectively detect B. besnoiti specific 
antibodies, in infected cattle sera, 948 reference samples were analyzed with the optimal 
conditions (mAb 3 at a dilution of 1:40 and, the positive control serum dilutions of 1:100 
and 1:1000). In addition, on each plate, a negative control serum was tested at a dilution 
of 1:2 (i.e. the dilution at which samples were tested, too). To assess the diagnostic 
sensitivity, sera from herds with bovine besnoitiosis were used. In the past it has been 
shown that N. caninum and Sarcocystis spp. infections may cause false positive results in 
B. besnoiti ELISAs. Thus, we used sera from herds with bovine neosporosis and herds 
with the presence of Sarcocystis infection to confirm diagnostic specificity of the Bb-
cELISA1. 
 
To validate the Bb-cELISA1, statistic parameters were determined. To summarize the 
performance of the Bb-cELISA1, several statistic parameters were calculated by a 
“Computing Optimal Cutpoints in Diagnostic Tests” managed with “R”. Based on the 
Youden's index an optimal inhibition cut-off of 49% was determined, resulting in an 
estimate of the diagnostic sensitivity of 99.1% and a diagnostic specificity of 99.9%. At 
this cut-off the test had a positive predictive value of 99.6 % and the negative predictive 
value of 99.7%; there was only one false positive and two false negative results (Table 
10).  
In summary, the statistical analysis revealed that the Bb-cELISA1 had a high diagnostic 
sensitivity and a high diagnostic specificity for the detection of bovine antibodies against 
B. besnoiti. Thus, these results suggest that the Bb-cELISA1 could be used as a stand-
alone test for herd monitoring programs, without the need for a confirmatory test. 
 
Summarizing, mAb 3 is an IgG1 isotype antibody with a Kappa light chain. It was 
produced by the hybridoma cell line 1/24-9/9-4 and showed high reactivity against the 
APure-BbELISA Ag when tested in iELISA. Under non-reducing conditions the epitope 
characterization showed a high molecular mass protein band (> 97.4 kDa) and three 
further reaction bands at 22.5 kDa, 21.0 kDa and 15.9 kDa in tachyzoite antigens. Under 
reduced conditions a strong protein band of 42.5 kDa was noticed in the B. besnoiti 
tachyzoite antigen. Regarding the B. besnoiti bradyzoite antigen, a high molecular mass 
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protein band (> 97.4 kDa) was recognized, both, under reducing and non-reducing 
conditions. A diffuse band of proteins was detected in the membrane of APure-BbELISA 
Ag in non-reducing conditions, strong reactions were visualized with the following 
molecular masses > 97.4 kDa, 21.6 kDa, and 16.8 kDa and two further reactions (22.8 
kDa and 22.1 kDa). No reactions were visualized in T. gondii tachyzoites and N. caninum 
tachyzoite antigens. 
 
In comparison to the iELISA, the Mab-based Bb-cELISA1 has the advantage of only 
requiring an Anti-mouse HRP-conjugated secondary Ab, instead of the need of a variety 
of HRP-conjugated secondary Ab specific, each specific for the tested species. Thus, the 
Bb-cELISA1 assay can be applied in testing different animal species. This fact can be 
helpful for further research on the life cycle of B. besnoiti, still remaining so mysterious.  
 
This study represents the first attempt on a Mab-based cELISA test for B. besnoiti 
infection in cattle. The aim to establish such test was successfully accomplished. 
However, the method still needs to be optimized. In order to save time, it would be better 
to reduce steps of the cELISA protocol (e.g., the possibility to block the plate with a 
blocking solution in which the mAb is already included, needs to be evaluated). This 
option eliminates the step of applying the mAb after the animal serum would save 
approximately 30 minutes. As an alternative, the addition of the diluted mAb directly to 
the diluted serum seems to be possible. This was suggested by Lunt et al. (1988). We 
think that it would be interesting to explore these options. Moreover, there is further the 
possibility that this test can be applied with the same efficiency, when the ELISA plate is 
coated with crude B. besnoiti Ag instead of the purified APure-BbELISA Ag. This 
modification may provide a more economic test, as time consuming and costly antigen 
purification can be avoided.  
 
Mabs have several applications and thirteen mAbs were characterized in this study. The 
ability of mAbs to capture the antigen could also be used for antigen detection by 
sandwich (or capture antigen) ELISA or another serological test that might be more 
practical to use in the field. 
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Moreover, monoclonal antibodies may be helpful by giving us some information about 
the exact role that antibodies play in resistance to B. besnoiti and the mechanisms by 
which the parasite survives. 
In further studies an IFAT could be performed since this allows the visual localization of 
the epitopes that each of the mAbs recognizes in and on parasitic stages, this technique 
was not performed in this study.  
 
Conclusion 
 
Since 2010, bovine besnoitiosis is considered a re-emerging disease and endemic in 
Europe according to EFSA and there is evidence of an increased number of cases and 
geographic expansion of the B. besnoiti infection and the associated disease.  Because 
clinical cases represent the iceberg's tip and are relatively sporadic in endemic herds, 
diagnosis must identify asymptomatic cattle that subsequently constitute a reservoir of 
bovine besnoitiosis. 
 
Thirteen mAbs were previously generated against an enriched membrane extract of B. 
besnoiti (APure BbELISA). This study describes several techniques essential to achieve 
a complete as possible characterization of the mAbs using iELISA and Immunoblot assay. 
The aim to establish a specific, sensitive, rapid and economic technique was successfully 
accomplished with a diagnostic sensitivity of 99.1% and a diagnostic specificity of 
99.9%. However, the method still needs to be improved, in order to reach a more rapid 
and economic technique. 
 
The accurate impact of this re-emerging disease has not been determined so far and, 
studies on the prevalence and incidence may be an important contribution. Our results 
suggests that the Bb-cELISA1 could be used as a stand-alone test for herd monitoring 
programs, without the need for a confirmatory test and contribute as well to the 
implementation of control strategies in the already affected and also at risk areas.  
To conclude, the Bb-cELISA1 represents a valuable tool for the diagnosis and control of 
bovine besnoitiosis and for epidemiology studies of B. besnoiti infections in a variety of 
host species. 
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